BHV-8000, a Selective Brain-Penetrant TYK2/JAK1 Inhibitor in Development for Neuroinflammatory and Neurodegenerative Diseases, Demonstrates Favorable PK/PD and Safety Profile in Phase 1 Studies (P9-2.010)
Year: 2025
Type: article
Study design: Clinical Trial
Source: Neurology
Authors: Lindsey Lee Lair, Peter Ackerman, Raj Bhardwaj, Bavani Shankar, Bharat Awsare, Randall Killingsworth, Eric Ashbrenner, Jo Ann Malatesta, Janet Plummer, Richard Bertz, Bruce Car, Irfan Qureshi, Vlad Coric
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4409227284